May 31,2023

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying cancer biology. In this study the researchers aimed to investigate the application of deep learning on chest CT scans to derive an imaging signature of response to immune checkpoint inhibitors and evaluate its added value in the clinical context. At the end, this proof-of-concept study shows that automated profiling of radiographic scans through deep learning can provide orthogonal information independent of existing clinicopathological biomarkers, bringing the goal of precision immunotherapy for patients with NSCLC closer.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 16,2023

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits

Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced the results of a recent study published in the Journal of Medical Economics, showing that Nerivio®, a novel Remote Electrical Neuromodulation (REN) wearable, provides significant cost savings in addition to clinical benefits when used as a preventive migraine treatment. The study found that, for a modeled US commercial health plan with one million members, covering Nerivio for all members clinically eligible for preventive treatment of migraine translates to an estimated $10,000 in annual cost savings per member and $560 million in annual savings for the plan.

CLINICAL STUDY

#connected device

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 20,2018

Research overview: Findings shared at the 2018 American Academy of Allergy, Asthma, and Immunology (AAAAI) Conference

Propeller, in collaboration with the Children’s Hospital Colorado, presented inhaler sensor data that assessed patterns of rescue and controller medication use among children and adults with self-reported persistent asthma. They found that patterns of inhaler use varied by age, time of day, and season. Results show that adolescents and young adults had lower rates of adherence compared to older adults who demonstrated improved adherence with increasing age. Adherence was highest in the winter months and declined in summer months.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

The majority of patients find remote care helpful. Clinicians can benefit from patient use, too.

Survey results from a recent Propeller Health study to be presented at the 2022 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting found that the majority of patients (68.7%) find their use of remote care helpful. Of the 441 patients surveyed, about one third of patients reported that they connected with their asthma providers through video visits and messaging services. In another Propeller Health study to be presented at the AAAAI Annual Meeting, Propeller found that monthly surveys conducted through its digital health app may be a feasible way to capture user-reported acute care events, potentially supporting early prediction of symptom worsening in patients with asthma.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Propeller Health research to be showcased at ERS International Congress 2021

The European Respiratory Society (ERS) International Congress, which took place virtually between September 5-8, 2021, is an annual event that brings together the world’s respiratory experts to present and discuss the latest scientific and clinical advances in the field of respiratory medicine. This year, the ERS accepted four abstracts authored by Propeller and its research partners ResMed and Novartis. The summary of the abstracts from the studies are announced by Propeller Health in advance.

CLINICAL STUDY

#mobile app

#rpm

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 06,2020

Findings on remote patient monitoring for better asthma control: Research posters from AAAAI 2020

The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting couldn’t take place this year due to the novel coronavirus (COVID-19) pandemic. However, there’s still a wealth of newly published research posters from the conference available online. Propeller contributed to six posters with research partners at Northshore University Health System, Children’s Hospital Colorado and Northwestern University Feinberg School of Medicine.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
May 09,2023

NEW STUDY FINDS THAT FITTERFLY DIABETES DIGITAL THERAPEUTICS PROGRAM IMPROVES BLOOD SUGAR LEVELS AND PROMOTES WEIGHT LOSS IN PATIENTS WITH TYPE 2 DIABETES

A new research study published in JMIR Diabetes evaluated the real-world effectiveness of the Fitterfly Diabetes CGM digital therapeutic program for the management of glycemic control and weight in people with type 2 diabetes mellitus. The Fitterfly Diabetes CGM program, delivered through the Fitterfly mobile app coupled with continuous glucose monitoring (CGM) technology, provides users with tailored recommendations on nutrition based on personalized glycemic response data, exercise, and behavior modifications to help manage type 2 diabetes. This study analyzed de-identified data of 109 participants with type 2 diabetes. The program was delivered in 3 phases. First, the participants' CGM readings were observed for 1 week; next, they received diet- and exercise-based interventions via Fitterfly app and coaches (nutritionists, psychologists, and physiotherapists); and finally, the researchers tracked whether the participants were able to sustain these newly introduced lifestyle modifications over the next 3 months. The researchers found that, at the end of the 90-day program, about 85% of all participants observed an average reduction of 1.2% in hemoglobin A1c (HbA1c) levels.

CLINICAL STUDY

#mobile app

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
May 08,2023

Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting

Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA. The presented research demonstrates the use of real-world data to identify high-risk mild cognitive impairment (MCI) patients to develop a predictive model for patients at high-risk of progression to AD. In partnership with Aetion, the purpose of this study was to develop a predictive model for progression to AD in a population of MCI patients and to identify MCI patients at high risk of developing AD using MarketScan administrative claims. Predictive, claims-based model identifies MCI patients at higher risk of faster Alzheimer’s disease progression than similarly diagnosed patients

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 09,2023

Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users

DarioHealth announced the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users with type 2 diabetes compared to non-users, the first study completed by Sanofi U.S. under its strategic agreement with Dario. The study used de-identified user data from Dario and claims data, through tokenization, to build highly comparable groups through a meticulous matching method that matched 2,445 Dario users with 7,334 non-users. The difference-in-difference method was used to analyze changes between the start and end of the study period in each group and between Dario user and non-user groups, on predefined primary and secondary endpoints. In this retrospective cohort study, utilizing Dario demonstrated a significantly greater reduction in all-cause HCRU and inpatient hospitalization rates during 12-month follow-up compared with non-users receiving usual care.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 05,2023

Akili Interactive Announces Its Clinical Trial Results on EndeavorRx for ADHD DTx

Akili Interactive, maker of a video game-like prescription digital therapeutic for children with ADHD, dubbed EndeavorRx, announced positive results of its clinical trial on the efficacy and safety of its offering among 221 adults with attention-deficit/hyperactivity disorder. The trial revealed that after six weeks of treatment with Akili's FDA-cleared product, EndeavorRx, adult participants had more than 80% improvement in attention functioning. More than one-third of these adults no longer showed signs of attention deficit following treatment.

CLINICAL STUDY

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY